Wedbush Forecasts Lower Earnings for Keros Therapeutics

Keros Therapeutics, Inc. (NASDAQ:KROS) – Wedbush dropped their FY2024 EPS estimates for Keros Therapeutics in a report released on Thursday, November 7th. Wedbush analyst Y. Zhong now anticipates that the company will post earnings per share of ($5.29) for the year, down from their prior forecast of ($5.14). Wedbush currently has a “Outperform” rating and a $84.00 price target on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.14) per share. Wedbush also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.40) EPS, Q1 2025 earnings at ($1.44) EPS, Q2 2025 earnings at ($1.46) EPS, Q3 2025 earnings at ($1.34) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.58) EPS, FY2026 earnings at ($5.54) EPS, FY2027 earnings at ($5.73) EPS and FY2028 earnings at ($4.73) EPS.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million during the quarter. During the same period in the prior year, the business earned ($1.33) earnings per share. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis.

Several other equities research analysts have also recently commented on the stock. Cantor Fitzgerald started coverage on shares of Keros Therapeutics in a research report on Thursday, October 24th. They set an “overweight” rating for the company. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Guggenheim assumed coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target on the stock. Bank of America decreased their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Finally, Scotiabank began coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price on the stock. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Stock Up 0.4 %

Shares of KROS stock opened at $68.15 on Monday. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of -13.08 and a beta of 1.23. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00. The stock has a 50-day moving average price of $58.65 and a 200 day moving average price of $52.23.

Institutional Investors Weigh In On Keros Therapeutics

A number of hedge funds have recently modified their holdings of the business. KBC Group NV grew its position in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares during the period. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics during the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Keros Therapeutics during the second quarter worth $128,000. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.